-
公开(公告)号:US5767094A
公开(公告)日:1998-06-16
申请号:US745048
申请日:1996-11-07
申请人: Kenji Tsujihara , Kunio Saito , Mitsuya Hongu , Mamoru Matsumoto , Kozo Oka
发明人: Kenji Tsujihara , Kunio Saito , Mitsuya Hongu , Mamoru Matsumoto , Kozo Oka
IPC分类号: A61K31/70 , A61K31/7028 , A61K31/7034 , A61K31/7048 , A61P3/08 , A61P3/10 , A61P43/00 , C07H15/203 , C07H15/26 , A01N43/04 , A01N43/16 , C07H15/00
CPC分类号: C07H15/203 , A61K31/70 , C07H15/26 , Y10S514/866
摘要: A propiophenone derivative the formula �I!: ##STR1## wherein R' is a lower alkanoyl group and R" is a hydrogen atom, or R' is a hydrogen atom and R" is a lower alkoxycarbonyl group, or a pharmaceutically acceptable salt thereof. Said compounds have excellent hypoglycemic activity so that they are useful in the prophylaxis or treatment of diabetes.
摘要翻译: 式[I]的苯丙酮衍生物:其中R'为低级烷酰基,R“为氢原子,或R'为氢原子,R”为低级烷氧基羰基,或 其药学上可接受的盐。 所述化合物具有优异的降血糖活性,因此它们可用于预防或治疗糖尿病。
-
公开(公告)号:US6048842A
公开(公告)日:2000-04-11
申请号:US993523
申请日:1997-12-18
申请人: Kenji Tsujihara , Kunio Saito , Mitsuya Hongu , Mamoru Matsumoto , Akira Oku
发明人: Kenji Tsujihara , Kunio Saito , Mitsuya Hongu , Mamoru Matsumoto , Akira Oku
IPC分类号: C07D401/12 , A61K31/4178 , A61P31/04 , C07H15/203 , C07H15/26 , A61K31/70 , C07H15/00
CPC分类号: C07H15/203 , C07H15/26 , Y02P20/55
摘要: A propiophenone derivative of the formula (I): ##STR1## wherein OX is a hydroxy group which may optionally be protected, Y is a lower alkyl group, and Z is a .beta.-D-glucopyranosyl group wherein one or more hydroxy groups may optionally be protected, or a pharmaceutically acceptable salt thereof. Said compounds have excellent hypoglycemic activity so that they are useful in the prophylaxis or treatment of diabetes.
摘要翻译: 式(I)的苯丙酮衍生物:其中OX是任选被保护的羟基,Y是低级烷基,Z是β-D-吡喃葡萄糖基,其中一个或多个羟基可以被任选地被保护, 或其药学上可接受的盐。 所述化合物具有优异的降血糖活性,因此它们可用于预防或治疗糖尿病。
-
公开(公告)号:US5830873A
公开(公告)日:1998-11-03
申请号:US429567
申请日:1995-04-27
IPC分类号: C07H15/203 , C07H15/26 , A61K31/70 , C07K15/00
CPC分类号: C07H15/203 , C07H15/26
摘要: A propiophenone derivative of the formula �I!: ##STR1## wherein X is O, S or methylene, OY is a protected or unprotected OH, Z is .beta.-D-glucopyranosyl or 4-O-(.alpha.-D-glucopyranosyl)-.beta.-D-glucopyranosyl or wherein one or more hydroxy groups of these groups may optionally be acylated, and the dotted line means the presence or absence of a double bond, or a pharmaceutically acceptable salt thereof. Said compounds have excellent hypoglycemic activity so that they are useful in the prophylaxis or treatment of diabetes.
摘要翻译: 式[I]的苯丙酮衍生物:其中X为O,S或亚甲基,OY为被保护或未被保护的OH,Z为β-D-吡喃葡萄糖基或4-O-(α-D- 吡喃葡萄糖基)-β-D-吡喃葡萄糖基或其中这些基团的一个或多个羟基可以任选地被酰化,并且虚线表示双键的存在或不存在或其药学上可接受的盐。 所述化合物具有优异的降血糖活性,因此它们可用于预防或治疗糖尿病。
-
公开(公告)号:US5731292A
公开(公告)日:1998-03-24
申请号:US426002
申请日:1995-04-20
IPC分类号: A61K31/7056 , C07H15/203 , A61K31/70
CPC分类号: A61K31/7034 , A61K31/7048 , A61K31/7056 , A61K31/706 , C07H15/203 , Y10S514/866
摘要: A method for prophylaxis or treatment of diabetes, which comprises administering to a patient with diabetes an effective amount of a dihydrochalcone derivative of the formula �I!: ##STR1## wherein Ar is an aryl group, R.sup.1 is hydrogen atom or an acyl group, R.sup.2 is a hydrogen atom, an acyl group or .alpha.-D-glucopyranosyl group, or R.sup.1 and R.sup.2 may combine together to form a substituted methylene group, R.sup.3 and R.sup.4 are each a hydrogen atom or an acyl group, OR.sup.5 is a protected or unprotected hydroxy group or a lower alkoxy group, or a pharmaceutically acceptable salt thereof.
摘要翻译: 一种预防或治疗糖尿病的方法,其包括向糖尿病患者施用有效量的式[I]的二氢查耳酮衍生物:其中Ar是芳基,R 1是氢原子或 酰基,R2是氢原子,酰基或α-D-吡喃葡萄糖基,或者R1和R2可以结合在一起形成取代的亚甲基,R 3和R 4各自为氢原子或酰基,OR 5为 保护或未保护的羟基或低级烷氧基,或其药学上可接受的盐。
-
公开(公告)号:US5424406A
公开(公告)日:1995-06-13
申请号:US149912
申请日:1993-11-10
IPC分类号: A61K31/70 , A61K31/7056 , C07H15/203 , C07H7/04 , C07H15/04
CPC分类号: A61K31/7034 , A61K31/70 , A61K31/7048 , A61K31/7056 , A61K31/706 , C07H15/203
摘要: A method for treatment of diabetes, which comprises administering to a patient with diabetes an effective amount of a dihydrochalcone derivative of the formula: ##STR1## wherein Ar is an aryl group, R.sup.1 is a hydrogen atom or an acyl group, R.sup.2 is a hydrogen atom, an acyl group or .alpha.-D-glucopyranosyl group, or R.sup.1 and R.sup.2 may combine together to form a substituted methylene group, R.sup.3 and R.sup.4 are each a hydrogen atom or an acyl group, OR.sup.5 is a protected or unprotected hydroxy group or a lower alkoxy group; or a pharmaceutically acceptable salt thereof.
摘要翻译: 一种治疗糖尿病的方法,其包括向糖尿病患者施用有效量的下式的二氢查耳酮衍生物:其中Ar为芳基,R 1为氢原子或酰基,R 2为氢 原子,酰基或α-D-吡喃葡萄糖基,或R 1和R 2可以结合在一起形成取代的亚甲基,R 3和R 4各自为氢原子或酰基,OR 5为被保护或未被保护的羟基或 低级烷氧基; 或其药学上可接受的盐。
-
公开(公告)号:US07345068B2
公开(公告)日:2008-03-18
申请号:US10503125
申请日:2003-02-03
申请人: Hitoshi Endou , Yoshikatsu Kanai , Kenji Tsujihara , Kunio Saito
发明人: Hitoshi Endou , Yoshikatsu Kanai , Kenji Tsujihara , Kunio Saito
IPC分类号: C07D235/14 , C07D263/57 , A61K31/54 , A61K31/4745
CPC分类号: C07D207/325 , C07C229/36 , C07C233/47 , C07C233/69 , C07C255/54 , C07C271/10 , C07C2602/10 , C07D209/08 , C07D213/30 , C07D213/74 , C07D215/14 , C07D235/18 , C07D239/42 , C07D263/32 , C07D263/56 , C07D265/36 , C07D277/24 , C07D277/66 , C07D307/79 , C07D307/82 , C07D307/83 , C07D307/91 , C07D311/30 , C07D401/04 , C07D413/04 , C07D417/04 , C07D471/06 , Y02P20/55
摘要: 1. An aromatic amino acid derivative represented by the formula (I) or its pharmacologically acceptable salt: wherein, R1 is a hydrogen atom or an amino-protecting group, R2 is a halogen atom or an alkyl, aralkyl or aryl group, R3 is {circle around (1)} a hydrogen atom, {circle around (2)} an aroylamino group, {circle around (3)} a phenyl group substituted with lower alkyl, phenyl, phenoxy, etc. {circle around (4)} a naphthyl or tetrahydronaphthyl group optionally substituted with hydroxy, lower alkoxy or di(lower)alkylamino, {circle around (5)} an unsaturated mono-cyclic heterocyclic group containing N, O and/or S substituted with lower alkyl, phenyl, naphthyl or tetrahydroquinolyl, {circle around (6)} an unsaturated or partially saturated condensed heterocyclic group containing N, O and/or S, optionally substituted with oxo, carboxy, amino, lower alkyl, etc.; X is a halogen atom, an alkyl group or an alkoxy group; Y is oxygen atom or nitrogen atom; l is 0 or 1; m is 0, 1 or 2; n is an integer of 0-5. This compound can inhibit a transporter (LAT1) of essential amino acid which is one of main nutrition for cancer cells and accordingly cause drain of the essential amino acid on the cancer cells and finally can prohibit the multiplication of cancer cells.
摘要翻译: 1.由式(I)表示的芳族氨基酸衍生物或其药理学上可接受的盐:其中R 1是氢原子或氨基保护基,R 2 O >是卤素原子或烷基,芳烷基或芳基,R 3是(环绕(1个氢原子,{环周围(2个芳酰氨基,{环周(3个苯基) 取代为低级烷基,苯基,苯氧基等。(四个萘基或四氢萘基,任选被羟基,低级烷氧基或二(低级)烷基氨基取代,(环绕(5个含有N的不饱和单环杂环基) O和/或S被低级烷基,苯基,萘基或四氢喹啉基取代,{环绕(6个不饱和或部分饱和的含有N,O和/或S的稠合杂环基,任选被氧代,羧基,氨基,低级烷基, X是卤素原子,烷基或烷氧基; Y是氧原子或氮原子; l是0或1; m 是0,1或2; n是0-5的整数。 该化合物可以抑制作为癌细胞的主要营养素之一的必需氨基酸的转运体(LAT1),因此导致癌细胞上必需氨基酸的排出,最终能够抑制癌细胞的增殖。
-
公开(公告)号:US5741816A
公开(公告)日:1998-04-21
申请号:US466968
申请日:1995-06-06
申请人: Kenji Tsujihara , Kunio Saito , Satoshi Furuuchi
发明人: Kenji Tsujihara , Kunio Saito , Satoshi Furuuchi
IPC分类号: A61K8/44 , A61Q7/00 , C07C229/22 , A01N37/02 , A01N37/06
CPC分类号: A61Q7/00 , A61K8/44 , C07C229/22 , Y10S514/88
摘要: Disclosed is a hair-growing (restoration) agent which comprises a carnitine compound represented by the formula (I): ##STR1## wherein R.sup.1 to R.sup.3 each represent an alkyl group having 1 to 6 carbon atoms; R.sup.4 represents an aliphatic acyl group having 3 to 31 carbon atoms which may be substituted; R.sup.5 represents an alkyl group having 3 to 31 carbon atoms which may be substituted, or an alkenyl group having 3 to 31 carbon atoms which may be substituted; and X.sup.- represents an anion of a pharmaceutically acceptable acid, as an active ingredient.
摘要翻译: 公开了包含式(I)表示的肉碱化合物的生发(还原剂):其中R 1至R 3各自表示具有1至6个碳原子的烷基; R4表示可以被取代的碳原子数3〜31的脂肪族酰基, R5表示可以被取代的碳原子数3〜31的烷基或可以被取代的碳原子数3〜31的烯基; X表示药学上可接受的酸的阴离子作为活性成分。
-
公开(公告)号:US20050119256A1
公开(公告)日:2005-06-02
申请号:US10503125
申请日:2003-02-03
申请人: Hitoshi Endo , Yoshikatsu Kanai , Kenji Tsujihara , Kunio Saito
发明人: Hitoshi Endo , Yoshikatsu Kanai , Kenji Tsujihara , Kunio Saito
IPC分类号: A61P35/00 , A61P43/00 , C07C229/36 , C07C233/47 , C07C233/69 , C07C255/54 , C07C271/10 , C07D207/32 , C07D207/325 , C07D209/08 , C07D213/30 , C07D213/74 , C07D215/14 , C07D235/18 , C07D239/42 , C07D263/32 , C07D263/56 , C07D265/36 , C07D277/24 , C07D277/66 , C07D307/79 , C07D307/82 , C07D307/83 , C07D307/91 , C07D311/30 , C07D401/04 , C07D413/04 , C07D417/04 , C07D471/06 , A61K31/54 , A61K31/4745
CPC分类号: C07D207/325 , C07C229/36 , C07C233/47 , C07C233/69 , C07C255/54 , C07C271/10 , C07C2602/10 , C07D209/08 , C07D213/30 , C07D213/74 , C07D215/14 , C07D235/18 , C07D239/42 , C07D263/32 , C07D263/56 , C07D265/36 , C07D277/24 , C07D277/66 , C07D307/79 , C07D307/82 , C07D307/83 , C07D307/91 , C07D311/30 , C07D401/04 , C07D413/04 , C07D417/04 , C07D471/06 , Y02P20/55
摘要: 1. An aromatic amino acid derivative represented by the formula (I) or its pharmacologically acceptable salt: wherein, R1 is a hydrogen atom or an amino-protecting group, R2 is a halogen atom or an alkyl, aralkyl or aryl group, R3 is {circle over (1)} a hydrogen atom, {circle over (2)} an aroylamino group, {circle over (3)} a phenyl group substituted with lower alkyl, phenyl, phenoxy, etc. {circle over (4)} a naphthyl or tetrahydronaphthyl group optionally substituted with hydroxy, lower alkoxy or di(lower)alkylamino, {circle over (5)} an unsaturated mono-cyclic heterocyclic group containing N, O and/or S substituted with lower alkyl, phenyl, naphthyl or tetrahydroquinolyl, {circle over (6)} an unsaturated or partially saturated condensed heterocyclic group containing N, O and/or S, optionally substituted with oxo, carboxy, amino, lower alkyl, etc.; X is a halogen atom, an alkyl group or an alkoxy group; Y is oxygen atom or nitrogen atom; I is 0 or 1; m is 0, 1 or 2; n is an integer of 0-5. This compound can inhibit a transporter (LAT1) of essential amino acid which is one of main nutrition for cancer cells and accordingly cause drain of the essential amino acid on the cancer cells and finally can prohibit the multiplication of cancer cells.
摘要翻译: 1.由式(I)表示的芳族氨基酸衍生物或其药理学上可接受的盐:其中R 1是氢原子或氨基保护基,R 2 O >是卤素原子或烷基,芳烷基或芳基,R 3是(在一个氢原子上的一个(1个氢原子,(2个芳酰基氨基,{在环上(3个苯基) (4个萘基或四氢萘基,任选被羟基,低级烷氧基或二(低级)烷基氨基取代,(环上)(5个不饱和单环杂环基含有N, O和/或S被低级烷基,苯基,萘基或四氢喹啉基取代,{在(6表示含有N,O和/或S的不饱和或部分饱和的稠合杂环基,可以被氧代,羧基,氨基,低级烷基, X是卤素原子,烷基或烷氧基; Y是氧原子或氮原子; I是0或1; m是0,1或 2; n是0-5的整数。 该化合物可以抑制作为癌细胞的主要营养素之一的必需氨基酸的转运体(LAT1),因此导致癌细胞上必需氨基酸的排出,最终能够抑制癌细胞的增殖。
-
公开(公告)号:US06617456B1
公开(公告)日:2003-09-09
申请号:US09624012
申请日:2000-07-21
IPC分类号: C07D49800
CPC分类号: C08B37/0018 , A61K47/61 , A61K47/65 , C08B37/0021
摘要: A camptothecin derivative comprising a compound of the formula [I]: wherein R1, R2, R3, R4 and R5 are (A) adjacent two groups combine to form alkylene, or both are H, and one of the remaining three groups is —Xn-Alkm-R6, and the other two are H, alkyl or halogen, or (B) adjacent two groups combine to form alkylene, and one of the carbon atoms of said alkylene group is substituted by —Xn-Alkm-R6, and the remaining three groups are H, alkyl or a halogen, and one or two —CH2— of the alkylene in (A) or (B) may optionally be replaced by —O—, —S— or —NH—, X is —O— or —NH—, Alk is alkylene, or —OH, m and n are both 0 or 1, or m is 1 and n is 0, which camptothecin compound is bound to a polysaccharide having carboxyl groups via an amino acid or a peptide, or a pharmaceutically acceptable salt thereof. Said camptothecin derivatives show enhanced antitumor activities but few side effects and are useful as a medicament.
摘要翻译: 包含式[I]化合物的喜树碱衍生物:其中R1,R2,R3,R4和R5是(A)相邻的两个基团结合形成亚烷基,或两者都是H,其余三个基团之一是-Xn -Alkm-R6,另外两个为H,烷基或卤素,或(B)相邻的两个基团结合形成亚烷基,所述亚烷基的一个碳原子被-Xn-Alkm-R6取代,并且 剩余的三个基团是H,烷基或卤素,并且(A)或(B)中的一个或两个亚烷基的-CH 2可以任选地被-O - , - S-或-NH-替代,X是-O - 或-NH-,Alk为亚烷基或-OH,m和n均为0或1,或m为1,n为0,喜树碱化合物通过氨基酸或肽与具有羧基的多糖结合 ,或其药学上可接受的盐。 所述喜树碱衍生物显示出增强的抗肿瘤活性,但副作用很少,可用作药物。
-
公开(公告)号:US5677470A
公开(公告)日:1997-10-14
申请号:US480052
申请日:1995-06-07
申请人: Kenji Tsujihara , Tomiki Hashiyama , Naoyuki Harada , Kunihiko Ozaki , Motoaki Ohashi , Noriyuki Nakanishi , Tetsuo Yamaguchi
发明人: Kenji Tsujihara , Tomiki Hashiyama , Naoyuki Harada , Kunihiko Ozaki , Motoaki Ohashi , Noriyuki Nakanishi , Tetsuo Yamaguchi
IPC分类号: C07D305/14 , C07D407/12 , C07D409/12
CPC分类号: C07D407/12 , A61K47/48038 , C07D305/14 , C07D409/12 , Y02P20/55
摘要: Disclosed are 13.alpha.-(3-substituted-2-hydroxypropionyloxy)baccatin compounds represented by the formula: ##STR1## wherein R.sup.1 represents a lower alkanoyl group or a protective group for hydroxy group; R.sup.2 represents a protective group for hydroxy group; R.sup.3 represents a lower alkanoyl group; R.sup.4 represents a substituted or unsubstituted benzoyl group; X represents a substituted or unsubstituted aryl group, a substituted or unsubstituted lower alkenyl group, or a substituted or unsubstituted lower alkynyl group; and A' represents a halogen atom, azido group or amino group, and processes for preparing the same.
摘要翻译: 公开了由下式表示的13α-(3-取代-2-羟基丙酰氧基)浆果赤霉素化合物:其中R1代表低级烷酰基或羟基保护基; R2表示羟基的保护基; R3表示低级烷酰基; R4表示取代或未取代的苯甲酰基; X表示取代或未取代的芳基,取代或未取代的低级烯基或取代或未取代的低级炔基; A'表示卤素原子,叠氮基或氨基,及其制备方法。
-
-
-
-
-
-
-
-
-